Locally advanced or metastatic Squamous Carcinoma of the Anal Canal

Non Resectable, Recurrent, or Metastatic Cholangiocarcinoma (Bladder)

ER+/HER2- Breast Cancer

HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer (ER+/PR+/HER2- )

Triple-Negative Breast Cancer

Clinical Data to Evaluate New Gene Expression Profiles (A Registry), All Comers Applicable

All Pathologies/Patients

Tripple Negative Breast Cancer (TNBC), Ovarian Cancer, Gynecologic Malignancies

HER2 Amplified Metastatic Breast Cancer

High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer

Gastrointestinal Malignancies (GEC, CRC)

Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

Advanced Squamous Cell Carcinoma of the Head and Neck

Squamous Cell Carcinoma of the Head and Neck, Non-Small Cell Lung Cancer, Melanoma, Renal Cell Carcinoma, Urothelial Cell Cancer

Myelodysplastic syndromes (MDS) or Acute Myeloid Leukemia (AML) on Bone Marrow

Non-Small Cell Lung Cancer High Tumor Mutation Burden

Non-Small Cell Lung Cancer, stages II-IIIA and IIIB (T>5cm N2) completely resected (R0)

Advanced Solid Tumor Malignancies, Any Loss of function mutation in CBL, Genetic Alteration in AXL

Stage IIIB (locally advanced or recurrent and not a candidate for curative therapy) or stage IV Advanced Non–Small-Cell Lung Cancer

Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer

Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors with RET fusion

Squamous Cell Carcinoma of the Head and Neck, Non-Small Cell Lung Cancer, Melanoma, Renal Cell Carcinoma, Urothelial Cell Cancer

All Pathologies/Patients

Follicular Lymphoma, Non-Hodgkin’s Lymphoma, Mantle Cell Lymphoma

Hodkin Lymphoma (HL) in Adults Age 60 and Above

Follicular Lymphoma with EZH2 mutation

All Pathologies/Patients

Squamous Cell Carcinoma of the Head and Neck, Non-Small Cell Lung Cancer, Melanoma, Renal Cell Carcinoma, Urothelial Cell Cancer

Myelofibrosis, post-poycythemia vera myelofibrosis, post essential thrombocytopenia myelo fibrosis

All Pathologies/Patients

Tripple Negative Breast Cancer (TNBC), Ovarian Cancer, Gynecologic Malignancies

Adenocarcinoma of Pancreas

Locally Advanced Pancreatic Adenocarcinoma

Castration-resistant Metastatic Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Metastatic Castration-resistant Prostate Cancer (mCRPC) with BRCA1/2 mutation or ATM

Metastatic Castration Resistant Prostate Cancer

All Pathologies/Patients

Squamous Cell Carcinoma of the Head and Neck, Non-Small Cell Lung Cancer, Melanoma, Renal Cell Carcinoma, Urothelial Cell Cancer

Advanced Solid Tumor Malignancies, Any Loss of function mutation in CBL, Genetic Alteration in AXL

Follicular Lymphoma with EZH2 mutation

Advanced Solid Tumor Malignancies, Any Loss of function mutation in CBL, Genetic Alteration in AXL

Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors with RET fusion

Advanced or Metastatic Urothelial Cancer

Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Metastatic or Surgically Unresectable Urothelial Cancer, Transitional Cell Carcinoma FGFR2, FGFR3 mutations.

urothelial or non-urothelial carcinoma of the urinary tract

Squamous Cell Carcinoma of the Head and Neck, Non-Small Cell Lung Cancer, Melanoma, Renal Cell Carcinoma, Urothelial Cell Cancer